

# Germline and somatic mutations in *STXBP1* with diverse neurodevelopmental phenotypes

OPEN

Mohammed Uddin, PhD  
Marc Woodbury-Smith,  
MD, PhD  
Ada Chan, MSc  
Ledia Brunga, MD  
Sylvia Lamoureux, BSc  
Giovanna Pellicchia, PhD  
Ryan K.C. Yuen, PhD  
Muhammad Faheem,  
PhD  
Dimitri J. Stavropoulos,  
PhD  
James Drake,  
MB, FRCSC  
Cecil D. Hahn, MD  
Cynthia Hawkins,  
MD, PhD  
Adam Shlien, PhD  
Christian R. Marshall,  
PhD  
Lesley A. Turner, MD  
Berge A. Minassian, MD  
Stephen W. Scherer, PhD  
Cyrus Boelman, MB

Correspondence to Dr. Boelman:  
cyrus.boelman@cw.bc.ca  
or Dr. Uddin:  
mohammed.uddin@mbru.ac.ae

## ABSTRACT

**Objective:** To expand the clinical phenotype associated with *STXBP1* gene mutations and to understand the effect of *STXBP1* mutations in the pathogenesis of focal cortical dysplasia (FCD).

**Methods:** Patients with *STXBP1* mutations were identified in various ways: as part of a retrospective cohort study of epileptic encephalopathy; through clinical referrals of individuals (10,619) with developmental delay (DD) for chromosomal microarray; and from a collection of 5,205 individuals with autism spectrum disorder (ASD) examined by whole-genome sequencing.

**Results:** Seven patients with heterozygous de novo mutations affecting the coding region of *STXBP1* were newly identified. Three cases had radiologic evidence suggestive of FCD. One male patient with early infantile epileptic encephalopathy, DD, and ASD achieved complete seizure remission following resection of dysplastic brain tissue. Examination of excised brain tissue identified mosaicism for *STXBP1*, providing evidence for a somatic mechanism. Cell-type expression analysis suggested neuron-specific expression. A comprehensive analysis of the published data revealed that 3.1% of severe epilepsy cases carry a pathogenic de novo mutation within *STXBP1*. By contrast, ASD was rarely associated with mutations in this gene in our large cohorts.

**Conclusions:** *STXBP1* mutations are an important cause of epilepsy and are also rarely associated with ASD. In a case with histologically proven FCD, an *STXBP1* somatic mutation was identified, suggesting a role in its etiology. Removing such tissue may be curative for *STXBP1*-related epilepsy. *Neurol Genet* 2017;3:e199; doi: 10.1212/NXG.000000000000199

## GLOSSARY

**ASD** = autism spectrum disorder; **CNV** = copy number variant; **DD** = developmental delay; **ddPCR** = droplet digital PCR; **EIEE** = early infantile epileptic encephalopathy; **FCD** = focal cortical dysplasia; **ID** = intellectual disability; **SNV** = single nucleotide variant.

Patients with *STXBP1* gene mutations live with 3 key phenotypic abnormalities: intellectual disability (ID), epilepsy, and movement disorders.<sup>1–4</sup> Epilepsy is often drug resistant and most commonly presents as severe early infantile epileptic encephalopathy (EIEE; Ohtahara syndrome) or West syndrome.<sup>4–6</sup> However, *STXBP1* mutations have been identified in patients with ID without epilepsy or with autism spectrum disorder (ASD).<sup>2,4,7</sup> This broad *STXBP1* encephalopathy phenotype is perhaps unsurprising, as *STXBP1* is involved in the synaptic release of neurotransmitters, with heterozygous mutations resulting in a reduction of both *STXBP1*'s protein product, syntaxin-binding protein 1, and syntaxin-1.<sup>8</sup> Moreover, homozygous deletions in knockout models are characterized by widespread brain apoptosis.<sup>9</sup> Although

From the Mohammed Bin Rashid University of Medicine and Health Sciences (M.U.), Dubai, UAE; The Centre for Applied Genomics (M.U., M.W.), Program in Genetics and Genome Biology (GGB) (A.C., L.B., S.L., G.P., R.K.C.Y., M.F., A.S., B.A.M., S.W.S.), Genome Diagnostics (D.J.S., C.R.M.), Paediatric Laboratory Medicine, Division of Neurosurgery (J.D., B.A.M.), and Division of Neurology (C.D.H.), The Hospital for Sick Children, Toronto, Ontario, Canada; Institute of Neuroscience (M.W.), Newcastle University, UK; Department of Molecular Genetics (A.C., S.W.S.), Department of Paediatrics (C.D.H., C.H.), and McLaughlin Centre (S.W.S.), University of Toronto, Ontario, Canada; Discipline of Genetics (L.A.T.), Faculty of Medicine, Memorial University of Newfoundland, St. John's, Canada; and Division of Neurology (C.B.), BC Children's Hospital, Vancouver, Canada.

Funding information and disclosures are provided at the end of the article. Go to [Neurology.org/ng](http://Neurology.org/ng) for full disclosure forms. The Article Processing Charge was funded by the Mohammed Bin Rashid University of Medicine and Health Sciences.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

there is evidence for a role in neurite growth,<sup>10</sup> the clinical pathophysiology remains unclear and sometimes spontaneously remitting epilepsy suggests developmental mechanisms beyond neurotransmission.

Radiologic evidence of gross brain pathology with heterozygous *STXBPI* mutations is variable.<sup>4,11</sup> When present, it suggests cerebral atrophy, abnormal myelination, or hypogenesis of the corpus callosum.<sup>12</sup> *STXBPI* germline mutation was reported only once in focal cortical dysplasia (FCD) but never a somatic mutation.<sup>13</sup> Molecular genetic studies of FCD to date has focused on *MTOR* pathway mutations.<sup>14</sup> We present a case series with *STXBPI* encephalopathy including a case with a radiologic diagnosis of FCD that went on to have successful epilepsy surgery.

Our aim was twofold: first, to investigate the histopathology and molecular biology of the excised brain tissue from an *STXBPI*-positive FCD patient; and second, to characterize the phenotypic spectrum of *STXBPI* through our case series and meta-analysis.

**METHODS Patients.** Patient 1 was part of a retrospective cohort study of patients with epileptic encephalopathy recruited using a standard protocol and with patient consent at The Hospital for Sick Children in Toronto between January 2012 and June 2014.<sup>15</sup> All patients underwent a series of investigations as part of their clinical workup, including chromosomal microarray and targeted next-generation sequencing using epilepsy panels for between 35 and 70 known epilepsy genes as previously described.<sup>15</sup> Additional patients with *STXBPI* deletions were identified through Toronto's Hospital for Sick Children, having been referred for clinical microarray and/or exome sequencing from a variety of clinical services in connection with concerns regarding epilepsy and/or developmental delay (DD) (10,619 microarrays).<sup>16</sup> In addition, an ASD cohort, forming part of the MSSNG project (mss.ng), was searched for *STXBPI* mutations. This project aims to sequence a minimum of 10,000 families and obtain detailed phenotypes. These families have been recruited from across Canada and/or are in the Autism Genetic Resource Exchange.<sup>17,18</sup> Molecular and computational methods have been previously described,<sup>19,20</sup> and lollipop software<sup>21</sup> was used to map mutations.

For meta-analysis, we have identified 162 cases with *STXBPI* mutations (single nucleotide variants [SNVs] or copy number variants [CNVs]) from numerous independent scientific reports (tables e-1 at <http://links.lww.com/NXG/A14>, and e-2 at <http://links.lww.com/NXG/A15>). For meta-analysis, we have used PubMed to review all of the described *STXBPI* scientific reports in the literature that were published up to September 2016. A total of 162 patients with heterozygous mutations of *STXBPI* have been described so far across 35 studies.

**Standard protocol approvals, registrations, and patient consents.** All patients described in this report have provided a written consent from the individuals involved or their substitute

decision makers, and the study was approved by The Hospital for Sick Children Research Ethics Board, Toronto, Canada.

**DNA extraction from resected brain tissue.** A portion of stock brain tissue (from patient 1) kept on dry ice was removed, added directly to cell lysis solution, and then homogenized using a sterile probe and an Omni tissue homogenizer. The homogenized tissue was digested overnight with Proteinase K at 55°C. This was repeated for the remaining visible tissue fragments for a further 5 hours at 55°C to ensure complete digestion. The tissue digest was subsequently spun down, and the supernatant was removed for extraction. High-salt Gentra protein precipitation solution was next added, and the sample was vortexed for 20 seconds and then put on ice for 5 minutes for complete precipitation. The sample was spun at 2,000g for 10 minutes, and all the supernatant was removed down to the protein pellet, leaving a thin layer above the pellet to prevent protein contamination. The supernatant was then transferred into isopropanol and inverted gently to mix 50 times to precipitate the DNA, which is then washed with 70% ethanol. This was then centrifuged and the ethanol was removed. Tris-EDTA buffer was next added to the dried DNA pellet for rehydration. After heating the DNA to 65°C for 1 hour, it was maintained on a rotator at room temperature overnight. DNA was then heated at 55°C for 1 hour and subsequently quantitated with a fluorometer using ds dye Hoescht.

**Immunohistochemistry.** For immunohistochemical studies on the resected brain tissue slice, hematoxylin and eosin staining was applied following a standard protocol, Olig2 staining against oligodendroglia-like cells and antineuronal nuclear antigen NeuN (Cat# MAB377, Millipore, Temecula, CA) against neurons with a dilution ratio of 1:50 were used following established protocols.<sup>22</sup>

**Droplet digital PCR.** We applied droplet digital PCR (ddPCR) technology to validate CNVs and to quantify the exact copy number. Copy number estimation of *STXBPI* was performed using the QX200 ddPCR system (Bio-Rad Laboratories, Inc., Hercules, CA) using the TaqMan copy number probe Hs00269332\_cn (Life Technologies, Carlsbad, CA). Prior to the copy number experiment, 250 ng of genomic DNA was digested with 4U of BtgI in a 10- $\mu$ L reaction buffer (New England Biolabs, Ipswich, MA), 1 hour  $\times$  37°C incubation, and no enzyme denaturation. The 20- $\mu$ L copy number reaction mix consisted of 10  $\mu$ L of 2 $\times$  ddPCR supermix for probes (Bio-Rad Laboratories), 1  $\mu$ L of the copy number target assay (labeled with FAM), 1  $\mu$ L of the copy number reference assay (RNaseP, Life Technologies, part 4403326, labeled with VIC), 6  $\mu$ L of water, and 2  $\mu$ L of 25 ng/ $\mu$ L digested genomic DNA. The copy number assay was validated by temperature gradient to ensure optimal separation of target and RNaseP-containing droplets. Cycling conditions for the reaction were 95°C for 10 minutes, followed by 45 cycles of 94°C for 30 seconds and 60°C for 1 minute, 98°C for 10 minutes and finally a 4°C hold on a Life Technologies Veriti thermal cycler. Data were analyzed with QuantaSoft v1.4 (Bio-Rad Laboratories). Two reference DNA samples (NA10843 and HuRef) plus 3 nontemplate controls were included with the study samples.

**RESULTS** We have identified 7 new patients with heterozygous de novo mutations affecting the coding region of *STXBPI*. Patient 1 was diagnosed with infantile spasms and global DD at age 3.5 months (table). Further evaluation at age 5 years identified

**Table** Clinical characteristics of patients with de novo *STXBP1* mutations


Phenotype	Sex	Chromosome coordinates (hg19)	Mutation type	Speech delay	Motor delay	ID	ASD	Other neurologic features	Epilepsy (seizure type [s])	EEG	Anticonvulsant response	MRI
Patient 1	M	130415943-130420935	Deletion (exon 3-4)	+	NA	+	+	-	+ (Infantile spasms; focal dyscognitive seizures with secondary generalization)	Bilateral anterior temporal epileptiform discharges	Seizure-free postepilepsy surgery; previously refractory to levetiracetam, clobazam, and vigabatrin	High FLAIR signal in anterior left superior and mesial temporal gyri, suspicious of focal cortical dysplasia (figure 1)
Patient 2	F	130427611	Splice-site G>T (c.663+1)	+	+	+	-	Bilateral intention tremor and upper limb dystonia	+ (Unclear types; possible epileptic spasms)	Diffuse slowing; focal and generalized epileptiform activity	NA	Normal
Patient 3	F	130430438	Missense C>T (p.Arg292Cys)	+	+	+	-	Head and hand tremor	+ (Tonic-clonic from 3 mo; focal clonic)	Multiple independent spike foci with left temporal-parietal focus at 3 mo; diffuse right hemisphere ictal focus at 6.5 y	Refractory to valproic acid, clonazepam, and phenobarbital	Incomplete myelination of anterior temporal poles; possible left anterior temporal FCD
Patient 4	M	130435529	Nonsense C>T (p.Arg367*)	+	+	+	-	-	+ (Infantile spasms)	Hypsarrhythmia at 5 mo; left posterior temporal then bifrontal epileptiform discharges by 2 y	Seizure-free on vigabatrin	Left anterior temporal lobe: asymmetric myelination or focal cortical dysplasia
Patient 5	F	130286582-130806948	Deletion	+	+	+	-	Tremor; ataxia; attention-deficit hyperactivity disorder; and obsessive compulsive disorder	+ (Brief generalized tonic seizures in infancy and rare nocturnal generalized tonic seizures at age 6 y)	Bilateral independent anterior temporal, central-temporal or posterior epileptiform discharges in early childhood; and normal at age 8 y	Partial then complete response to phenobarbital in infancy and no anticonvulsants after	Normal
Patient 6	F	130444715-130444717	Frameshift (p.Lys526Asnfs*23)	+	NA	+	+	-	+ (Absence; tonic-clonic)	NA	NA	NA
Patient 7	M	130428536	Missense T>C (p.Met252Thr)	+	-	+	+	Fluctuating gait abnormality	+ (Tonic-clonic seizures from 1 y; tonic; epileptic spasms)	Multiple independent spike foci at age 1 y, normalized then re-emerged at age 2.5 y; and left frontal and right temporal independent ictal foci	Refractory to valproic acid, topiramate, phenobarbital, and prednisone; partial response to ketogenic diet	Normal

Abbreviations: - = absent; + = present; ASD = autism spectrum disorder; FCD = focal cortical dysplasia; FLAIR = fluid-attenuated inversion recovery; ID = intellectual disability; NA = information unavailable.

social and communication impairments and behavioral features consistent with a diagnosis of ASD. At this time, he continued to present with DD, and his frequent focal dyscognitive seizures (paroxysmal onset of altered awareness, gazing around with an open mouth, and ending with a cough with or without emesis), with secondary generalization, were resistant to pharmacologic anticonvulsant treatments. EEG demonstrated bilateral frontotemporal spikes and waves, and MRI suggested FCD in the left medial temporal lobe, specifically affecting the superior

temporal, hippocampal, and parahippocampal gyri (figure 1A). Genetic evaluation using clinical microarray and a commercial 70-gene next-generation sequencing epilepsy panel (GeneDx, Gaithersburg, MD; table e-3 at <http://links.lww.com/NXG/A14>) identified a heterozygous partial deletion of exons 3–4 in *STXBP1*. Examination of parental genotypes confirmed the de novo nature of this deletion. No other clinically relevant genetic abnormality was identified on sequencing or microarray. In view of the intractable nature of his seizures, patient 1

**Figure 1** MRI of patient 1 with fluid-attenuated inversion recovery signal



(A) Axial MRI of patient 1 demonstrating diffuse cortical/subcortical high fluid-attenuated inversion recovery (FLAIR) signal confined to the anterior left superior temporal gyrus and mesial temporal structures (white boxes). (B–C) Subtle increased FLAIR signal in the anterior temporal lobes of patients 2 and 3, respectively, suggestive of possible cortical dysplasia.

subsequently underwent lesionectomy of the left anterior temporal horn at the age of 6 years, with complete remission of seizures achieved following resection and continuing as of the last follow-up 2 years later (both Engel and International League Against Epilepsy outcome Class 1). His ID and ASD remain symptomatically unchanged after surgery.

Resected dysplastic tissue and marginal nondysplastic tissue were histologically examined. While normal histology was evident in most of the imaging-suggested dysplastic tissue, the superior temporal gyrus showed heterotopic neurons in the white matter, blurring the gray–white matter junction, and in the deeper temporal white matter, there were nodular heterotopias comprising dysplastic tissue representing collections of cells with small round nuclei and clear cytoplasm, possibly immature neurons (figure 2, A–D). Immunohistochemistry labeling with both NeuN and Olig2 was negative in the latter. These findings were most consistent with FCD-type Ib.<sup>23</sup> To further evaluate the molecular basis of patient 1 with epilepsy and ID, we undertook ddPCR on resected left lateral temporal cortical tissue and marginally resected normal brain tissue, hypothesizing that dysplastic tissue may be characterized by mosaicism for *STXBPI*. As predicted, copy number quantification was consistent with haploinsufficiency in marginal tissue but mosaicism in dysplastic


tissue. The quantification (below 1 copy; figure 2E) was confirmed on 7 independent replications, consistent with cells mosaic for heterozygous and homozygous *STXBPI* mutations in the dysplastic tissue. To characterize the cellular impact of mosaicism, we analyzed *STXBPI* transcriptome profiles from 466 single cells<sup>24</sup> for 6 major brain cells—astrocytes, microglia, neurons, endothelial, oligodendrocytes, and oligodendrocyte precursor cells. *STXBPI* encodes syntaxin-binding protein that plays a role in the release of neurotransmitter through the regulation of syntaxin. Our analysis confirmed the principally neuronal expression of *STXBPI* (figure 2F) compared with other primary brain cell types. This neuron-specific expression pattern and the known pathway of syntaxin imply a functional relevance of this gene into the etiology of epileptogenicity.

We identified 4 additional cases with heterozygous *STXBPI* mutations (patients 2, 3, and 4) or deletion (patient 5) through clinics and 10,619 samples referred for chromosomal microarray at The Hospital for Sick Children. These patients were identified with a de novo mutation or deletion effecting one or more exons of *STXBPI* (table). Two (patients 2 and 5) of our reported de novo mutations are novel and 2 (patients 3 and 4) were found to be recurrent mutations reported in previous literature. All presented with speech delay, global DD/ID, and epilepsy. Other more variable clinical features included motor delay and upper limb tremor (patients 2 and 3). Patients 3 and 4 also had MRI evidence of possible FCD (figure 1, B and C). The 7-year-old female (patient 3) presented at 3 months of age with multiple seizure types (including myoclonic, atonic, tonic–clonic, and focal dyscognitive seizures) and DD, with MRI demonstrating asymmetric increased T2 signal in the white matter of the anterior temporal poles, consistent with either delayed myelination or possibly left anterior temporal FCD. Although interictal EEG was abnormal bilaterally, ictal EEG demonstrated seizures arising from the contralateral right hemisphere. The 4-year-old male (patient 4) was similarly suspected to have delayed myelination or FCD at the left anterior temporal pole based on the increased T2 signal in the white matter. His interictal EEGs did not demonstrate epileptiform activity.

In view of patient 1’s diagnosis of ASD and the indication in the literature of several patients with “autistic features” or ASD diagnoses, we next investigated our ASD cohort for the evidence of *STXBPI* mutations. Of the currently sequenced individuals (5,205), 2 were identified with novel de novo variants overlapping *STXBPI* (table; patients 6 and 7). A female individual (patient 6) has a de novo frameshift mutation truncating the protein’s domain 2. Patient 7 is a male individual with a de novo missense mutation



**Figure 2** Histopathology of surgically excised dysplastic brain tissue (patient 1)



Circled areas of the left temporal lobe juxtacortical demonstrate linear neuronal heterotopia on (A) hematoxylin and eosin (H&E) and (B) NeuN stains, highlighting neurons; superior temporal gyrus nodular heterotopia are seen in boxes with (C) NeuN and (D) H&E stains, highlighting likely immature neurons; (E) Copy number variant mosaicism quantification using ddPCR within focal cortical dysplasia (red) and normal (black) tissue. The standard error bar shows the inferred copy number of approximately 20,000 droplets generated from each tissue type by the ddPCR; (F) single expression profile of the *STXBP1* gene in primary brain cell types. RNA-seq reads were obtained (GEO GSE67835) for *STXBP1* gene expression from 6 primary brain cell types (astrocytes, endothelial, microglia, neurons, oligodendrocytes, and oligodendrocyte progenitor cells [OPCs]). The bar showing lower 25th and upper 75th percentiles of the data, and the dots represent the outliers. Each color represents each cell types.

and primarily diagnosed with ASD with severe epilepsy. Both individuals were diagnosed with ASD using the ADI-R in conjunction with the ADOS. Both are nonverbal, with severe ASD in association with ID. Many of these individuals have also been investigated for the presence of CNVs by microarray.<sup>17</sup>

We subsequently reviewed all of the described *STXBP1* reports in the literature (up to September 2016). There have been a total of 162 patients with heterozygous mutations of *STXBP1* described so far across 35 studies (table e-1). For each mutation, we have converted the mutations into hg19 track and


inferred the corresponding protein changes. The mutation spectrum comprises different variants spread across all 3 domains of the gene, with 21 recurrent mutations in unrelated individuals occurring in domains 2 and 3 (figure 3A). Mutations include 121 SNVs and 15 indels (of size <100 bp), and a total of 26 cases were reported to have a CNV affecting *STXBP1*. Sex was available for 126 cases, and we observed a higher proportion of females reported to carry an *STXBP1* mutation compared with males, 57.1% (72) and 42.8% (54), respectively (figure 3B). Ascertainment for these 162 cases included 80% with a form of epilepsy syndrome (described as EIEE, Ohtahara syndrome, West syndrome, and Dravet syndrome) and 20% with one or more of the following: ASD, DD, movement disorder, nonsyndromic ID, and atypical Rett syndrome (figure 3C). Information pertaining to comorbidity for these 162 cases is not available.

A total of 140 variants (of 162) were reported to be de novo including case reports. To determine the rate

of de novo variants, we excluded all case reports and retained only those studies that analyzed a cohort (with at least 20 samples); all 19 studies were ascertained by way of a primary diagnosis of epilepsy. From these 19 studies (table e-1), a total of 2,569 cases were analyzed, among whom 80 were reported to have a variant within *STXBP1*. More than 92.5% (74 of 80) carried a de novo variant, with the remainder of unknown inheritance. We can compute, therefore, a rate of 3.1% for de novo mutations within *STXBP1* for cases with epilepsy. We realize that this de novo rate is high due to the selection of samples that are clinically well defined for epilepsy-related conditions.

**DISCUSSION** Through a review of over 18,393 cases of ASD and DD, with molecular and/or cytogenetic analysis and meta-analysis of the literature, we report the prevalence of *STXBP1* gene mutations in epilepsy as well as present an interesting finding of

**Figure 3** Mapping of mutations within the *STXBP1* gene



(A) Mutations mapped within the 3 protein domains (cyan— domain 1, green—domain 2, and red—domain 3a/b) of the *STXBP1* gene; (B) percentage of male and female cases reported to carry a pathogenic mutation for the *STXBP1* gene. (C) Clinical spectrum associated with de novo *STXBP1* mutations reported for early infantile epileptic encephalopathy (EIEE), focal cortical dysplasia (FCD), Ohtahara syndrome (OS), West syndrome (WS), Dravet syndrome, infantile spasms (ISs), neonatal refractory seizures, autism spectrum disorder, developmental delay, nonsyndromic intellectual disabilities (IDs), and atypical Rett syndrome.

somatic *STXBPI* mutation associated with FCD. Our detailed molecular analysis of excised brain tissue from patient 1 has revealed the observation of the postzygotic *STXBPI* mutation in excised focally dysplastic tissue, with sustained remission of the epilepsy following resective surgery, which highlights the clinical importance of this finding. Only one other patient has been described in the literature with a similar pattern.<sup>13</sup> This other patient, with a germline heterozygous deletion, presented clinically with ID and epilepsy. Despite having a normal MRI, she underwent surgical management of her seizures with near-complete remission achieved. FCD was demonstrated in resected tissue within the temporal lobe, although detailed molecular biology of the resected tissue, as we have newly done here, is not reported.

Patient 1's exemplary outcome following surgery is important and supports the relevance of a previous study with the observation of a good outcome.<sup>13</sup> Treatment-resistant epilepsy significantly decreases the quality of life and increases the risk of sudden unexpected death in an epilepsy patient.<sup>25</sup> Our observation suggests that presurgical evaluations should be aggressively pursued in patients with *STXBPI* when there is evidence of dominant focality and not limited out of concern for the presence of a germline mutation. Although only about 50% of cases described so far with heterozygous deletions of *STXBPI* have MRI evidence of brain pathology, milder type II and type I classified cortical dysplasias may be undiagnosed. Certainly, the limitation of current imaging sensitivity, even 3T MRI, is evidenced by a previous study<sup>13</sup> and the abnormal myelination vs FCD differential reported in 2 of our patients who did not have surgery.

Although more extensive studies are required to fully elucidate the genetics of FCD, the case described in this study provides a new lead. It remains possible that the FCD was an incidental finding in our reported case, but it does raise the possibility of a causal relationship between neuronal expression of mosaic *STXBPI* mutations and FCD. This association is supported by the homozygous *STXBPI* deletion being only identified in the dysplastic portions of the resected brain, and at low levels, perhaps just in neurons. Recent studies reported somatic mutations in *MTOR* in excised dysplastic brain tissue in 12 of 77 patients with epilepsy.<sup>26,27</sup> The implication is that somatic mutations may arise in brain tissue during development by an as-yet undetermined mechanism.<sup>28</sup> As has been presented and discussed at length in a previous study, even low levels of mosaicism in *MTOR* pathway genes may result in significant clinical pathology.<sup>14</sup> The *MTOR* gene was not sequenced in the 70-gene panel of patient 1 (table e-2), and there was insufficient dysplastic tissue to do this separately. With regard to potential *MTOR* mutations in our

case, even if present, we would not be able to tell whether those were in the same subclonal population as the dysplasia-specific *STXBPI* mosaicism. While somatic mutations have received much attention in cancer and certain nonbrain disorders, a possible etiopathologic connection with neurodevelopmental disorders, such as epilepsy and ASD, requires further elucidation. Our own study provides some impetus to further explore this possibility.

From a clinical genetics perspective, our study has calculated that 3.1% of clinically identified epilepsy cases harbor a rare/de novo mutation within *STXBPI*. Furthermore, our wider sampling of separate very large, "classic autism" ASD and DD cohorts allows us to conclude that *STXBPI* seems to be associated only with severe ASD and DD in the presence of epilepsy. We have shown that the epilepsy observed with *STXBPI* encephalopathy may be controlled through surgery by identifying dysplastic tissue, which is associated with further mosaic changes in *STXBPI* limited to dysplasia. These rare observations help define this disorder's phenotype and introduce interesting genotypic information underlying FCD.

#### AUTHOR CONTRIBUTIONS

M.U. and C.B. contributed to the conception and design of the study. A.C., L.B., S.L., G.P., R.K.C.Y., M.F., and A.S. helped analyze data. D.J.S., J.D., C.D.H., C.H., and L.A.T. contributed to sample recruitment, clinical data acquisition, and analysis. M.W.-S., C.R.M., B.M., S.W.S., M.U., and C.B. contributed to drafting the text and preparing the figures.

#### ACKNOWLEDGMENT

The authors thank The Centre for Applied Genomics (TCAG), which is funded by Genome Canada and the Ontario Genomics Institute, the Canada Foundation for Innovation (CFI), and the Ontario Research Fund of the Government of Ontario. The project was also supported by funds from the University of Toronto McLaughlin Centre and Genome Canada. M.U. holds a Banting postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR).

#### STUDY FUNDING

No targeted funding reported.

#### DISCLOSURE

M. Uddin has received travel funding from a nonprofit entity; was a Banting postdoctoral fellow from the Canadian Institutes of Health Research (CIHR); and has applied for a US patent for classifying mutation for autism and neurodevelopmental disorders. M. Woodbury-Smith is supported by a Clinical Investigatorship Award from the Canadian Institutes of Health Research's (CIHR) Institute of Genetics and has served on the editorial board of the *Journal of Autism and Developmental Disorders*. A. Chan has received research support from the Government of Ontario/Ontario Graduate Scholarship and the Government of Canada/Frederick Banting and Charles Best Scholarship. L. Brunga, S. Lamoureux, G. Pellecchia, R. Yuen, M. Faheem, D.J. Stavropoulos, and J. Drake report no disclosures. C. Hahn has served on the scientific advisory boards of SAGE Therapeutics and Marinus Pharmaceuticals; has served on the editorial boards of the *Journal of Clinical Neurophysiology* and *PLoS One*; is the second vice president of the American Clinical Neurophysiology Society and the President of the Canadian Society of Child Neurology; and has received research support from The Hospital for Sick Children Foundation and the American Epilepsy Society and Epilepsy Foundation of America. C. Hawkins has served on the scientific advisory board of the Pediatric Brain Tumor Consortium (nonprofit entity); has



served on the editorial boards of *Acta Neuropathologica Communications* and the *Journal of Neuropathology and Experimental Neurology*; holds a patent for BOC modulation and uses thereof for treating, preventing and/or diagnosing cancer; and has received research support from Bayer, Grants4Targets, the Canadian Institutes of Health Research, Medical Sciences Proof of Principle (MSc POP) Program, Genome Canada, the Canadian Cancer Society Research Institute, DIPG collaborative, and Curing Kids Cancer. A. Shlien has received research support from the Terry Fox Foundation. C.R. Marshall has received travel funding from Affymetrix and Life Technologies and has served on the editorial boards of *Genes, Genomes, Genetics* and the *Journal of Neurodevelopmental Disorders*. L.A. Turner has received research support from Shire and CIHR. B. Minasian holds patents for diagnostic testing of the following genes: EPM2A, EPM2B, MECP2, and VMA21; has received research support from NIH; and has received license fee payments/royalty payments from patents for diagnostic testing of the following genes: EPM2A, EPM2B, MECP2, and VMA21. S.W. Scherer holds the GlaxoSmithKline-CIHR Chair in Genome Sciences at the University of Toronto and The Hospital for Sick Children; has served on the scientific advisory board of Population Diagnostics; has served on the editorial boards of *Genomic Medicine, Genes, Genomes, Genetics, the Journal of Personalized Medicine, the Open Genomics Journal, the Hugo Journal, Genome Medicine, the Journal of Neurodevelopmental Disorders, Autism Research, PathoGenetics, Comparative and Functional Genomics, BMC Medical Genomics, and Cytogenetics and Genome Research*, and has received research support from Genome Canada/Ontario Genomics Institute, Canadian Institutes of Health Research, Canadian Institute for Advanced Research, McLaughlin Centre, Canada Foundation for Innovation, government of Ontario, and NIH. C. Boelman reports no disclosures. Go to [Neurology.org/ng](http://Neurology.org/ng) for full disclosure forms.

Received April 26, 2017. Accepted in final form August 30, 2017.

## REFERENCES

- Gburek-Augustat J, Beck-Woedl S, Tzschach A, Bauer P, Schoening M, Riess A. Epilepsy is not a mandatory feature of STXBP1 associated ataxia-tremor-retardation syndrome. *Eur J Paediatr Neurol* 2016;20:661–665.
- Hamdan FF, Piton A, Gauthier J, et al. De novo STXBP1 mutations in mental retardation and nonsyndromic epilepsy. *Ann Neurol* 2009;65:748–753.
- Mignot C, Moutard ML, Trouillard O, et al. STXBP1-related encephalopathy presenting as infantile spasms and generalized tremor in three patients. *Epilepsia* 2011;52:1820–1827.
- Stamberger H, Nikanorova M, Willemsen MH, et al. STXBP1 encephalopathy: a neurodevelopmental disorder including epilepsy. *Neurology* 2016;86:954–962.
- Otsuka M, Oguni H, Liang JS, et al. STXBP1 mutations cause not only Ohtahara syndrome but also West syndrome—result of Japanese cohort study. *Epilepsia* 2010;51:2449–2452.
- Saito H, Kato M, Mizuguchi T, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. *Nat Genet* 2008;40:782–788.
- Milh M, Villeneuve N, Chouchane M, et al. Epileptic and nonepileptic features in patients with early onset epileptic encephalopathy and STXBP1 mutations. *Epilepsia* 2011;52:1828–1834.
- Patzke C, Han Y, Covy J, et al. Analysis of conditional heterozygous STXBP1 mutations in human neurons. *J Clin Invest* 2015;125:3560–3571.
- Grone BP, Marchese M, Hamling KR, et al. Epilepsy, behavioral abnormalities, and physiological comorbidities in syntaxin-binding protein 1 (STXBP1) mutant zebrafish. *PLoS One* 2016;11:e0151148.
- Yamashita S, Chiyonobu T, Yoshida M, et al. Mislocalization of syntaxin-1 and impaired neurite growth observed in a human iPSC model for STXBP1-related epileptic encephalopathy. *Epilepsia* 2016;57:e81–e86.
- Di Meglio C, Lesca G, Villeneuve N, et al. Epileptic patients with de novo STXBP1 mutations: key clinical features based on 24 cases. *Epilepsia* 2015;56:1931–1940.
- Barcia G, Chemaly N, Gobin S, et al. Early epileptic encephalopathies associated with STXBP1 mutations: could we better delineate the phenotype? *Eur J Med Genet* 2014;57:15–20.
- Weckhuysen S, Holmgren P, Hendrickx R, et al. Reduction of seizure frequency after epilepsy surgery in a patient with STXBP1 encephalopathy and clinical description of six novel mutation carriers. *Epilepsia* 2013;54:e74–e80.
- Mirzaa GM, Campbell CD, Solovieff N, et al. Association of MTOR mutations with developmental brain disorders, including megalencephaly, focal cortical dysplasia, and pigmented mosaicism. *JAMA Neurol* 2016;73:836–845.
- Mercimek-Mahmutoglu S, Patel J, Cordeiro D, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. *Epilepsia* 2015;56:707–716.
- Uddin M, Pellicchia G, Thiruvahindrapuram B, et al. Indexing effects of copy number variation on genes involved in developmental delay. *Scientific Rep* 2016;6:28663.
- Pinto D, Delaby E, Merico D, et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. *Am J Hum Genet* 2014;94:677–694.
- Uddin M, Tammimies K, Pellicchia G, et al. Brain-expressed exons under purifying selection are enriched for de novo mutations in autism spectrum disorder. *Nat Genet* 2014;46:742–747.
- Yuen RK, Merico D, Cao H, et al. Genome-wide characteristics of de novo mutations in autism. *NPJ Genomic Med* 2016;1:160271–1602710.
- Yuen RK, Thiruvahindrapuram B, Merico D, et al. Whole-genome sequencing of quartet families with autism spectrum disorder. *Nat Med* 2015;21:185–191.
- Jay JJ, Brouwer C. Lollipops in the clinic: information dense mutation plots for precision medicine. *PLoS One* 2016;11:e0160519.
- Krzisch M, Temprana SG, Mongiat LA, et al. Pre-existing astrocytes form functional perisynaptic processes on neurons generated in the adult hippocampus. *Brain Struct Funct* 2015;220:2027–2042.
- Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. *Epilepsia* 2011;52:158–174.
- Darmanis S, Sloan SA, Zhang Y, et al. A survey of human brain transcriptome diversity at the single cell level. *Proc Natl Acad Sci USA* 2015;112:7285–7290.
- Hall-Patch L, Gayatri N, Ferrie C, Morrall MC. Clinical reasoning and investigations for resective surgery for medically refractory epilepsies in children. *Epilepsy Behav* 2012;23:442–446.
- Lim JS, Kim WI, Kang HC, et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. *Nat Med* 2015;21:395–400.
- Lim ET, Uddin M, De Rubeis S, et al. Rates, distribution and implications of postzygotic mosaic mutations in autism spectrum disorder. *Nat Neurosci* 2017;20:1217–1224.
- Poduri A, Evrony GD, Cai X, Walsh CA. Somatic mutation, genomic variation, and neurological disease. *Science* 2013;341:1237758.